Renzapride
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 4-amino-N-[(4S,5S)-1-azabicyclo[3.3.1]non-4-yl]-5-chloro-2-methoxybenzamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 109872-41-5  |
| ATC code | None |
| PubChem | CID 3086547 |
| IUPHAR ligand | 244 |
| ChemSpider | 16736758  |
| UNII | 9073C0W4E9 |
| ChEMBL | CHEMBL289753 |
| Chemical data | |
| Formula | C16H22ClN3O2 |
| Mol. mass | 323.818 g/mol |
|
|
|
|
 (what is this?) (verify) |
Renzapride is a gastroprokinetic agent and antiemetic which acts as a full 5-HT4 full agonist and 5-HT3 antagonist.[1][2] It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors, though it is unlikely that these properties contribute to its therapeutic effects.[1]
Renzapride was being developed by Alizyme plc of the United Kingdom.
Clinical trials [edit]
Renzapride was being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme plc of the United Kingdom.
As of 23 April 2008, Alizyme ceased all development of renzapride, after a Phase III trial in the U.S. did not show enough efficacy over placebo to justify further development.[3]
References [edit]
- ^ a b Meyers NL, Hickling RI. (2008). "Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.". Drugs R D. 9 (1): 37–63. PMID 18095752.
- ^ Camilleri M., McKinzie S., Fox J., Foxx-Orenstein A., Burton D., Thomforde G., Baxter K. and Zinsmeister A. R. (2004). "Effect of Renzapride on Transit in Constipation-Predominant Irritable Bowel Syndrome", Clin. Gastroent. and Hepatology; 2:895-904
- ^ "Results from Renzapride" (Press release). Alizyme plc. 23 April 2008. Retrieved 7 May 2009.
|
|
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
